Novartis AG (NVSEF) Free cash flow 2016–2025
Novartis AG (NVSEF) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$17.6BFY2025 · since FY2016: $9.6B → $17.6B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $17.6B | +8.3% |
| FY2024 | $16.3B | +21.3% |
| FY2023 | $13.4B | +0.6% |
| FY2022 | $13.3B | -4.9% |
| FY2021 | $14.0B | +13.2% |
| FY2020 | $12.4B | +1.1% |
| FY2019 | $12.2B | -5.9% |
| FY2018 | $13.0B | +15.2% |
| FY2017 | $11.3B | +17.5% |
| FY2016 | $9.6B | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice